What Is CJC-1295 + Ipamorelin?
Last reviewed:
CJC-1295 (No DAC) + Ipamorelin is a research blend that pairs a modified growth-hormone-releasing hormone (GHRH) analogue with a selective growth-hormone secretagogue. Research on the individual compounds examines the growth-hormone / IGF-1 axis. The long-acting, albumin-binding CJC-1295 studied in the original papers is distinct from the No-DAC material in this blend. These are investigational compounds and are not approved medicines.
How are CJC-1295 and Ipamorelin classified?
- CJC-1295 (No DAC) — a modified GHRH (1–29) analogue; “No DAC” denotes the form without the Drug Affinity Complex modification.
- Ipamorelin — a selective pentapeptide growth-hormone secretagogue that acts at the ghrelin / growth-hormone-secretagogue (GHS) receptor.
How is the CJC-1295 + Ipamorelin mechanism studied in research?
Research characterises the two components by their receptor targets:
- CJC-1295 — studied at the GHRH receptor.
- Ipamorelin — studied at the ghrelin / GHS receptor, noted in the literature for its selectivity.
The cited studies examine individual compounds and receptor pharmacology; they do not establish the properties of this No-DAC combination.
These statements describe the published scientific record; they are not claims about any effect in humans.
What kind of research has been published on CJC-1295 and Ipamorelin?
Raun et al. (1998) characterised Ipamorelin in cell and animal models. For CJC-1295, Alba et al. (2006) studied mice and Ionescu and Frohman (2006) studied human participants; both papers describe a long-acting analogue that binds to albumin. They did not test CJC-1295 (No DAC) + Ipamorelin, so their duration-of-action findings cannot be transferred to this blend. The other references cover receptor classification, analytical characterisation and receptor structure, including a 2025 cryo-electron-microscopy study in Nature Structural & Molecular Biology.
What compounds are CJC-1295 and Ipamorelin studied alongside?
In the published literature, CJC-1295 is grouped with other GHRH analogues such as sermorelin and tesamorelin — one analytical study characterised all three in a single method — while Ipamorelin sits in the growth-hormone-secretagogue class first benchmarked against GHRP-2 and GHRP-6. These groupings describe how the compounds are classified in published research; they do not imply equivalence between compounds or any human-use indication.
How is CJC-1295 + Ipamorelin supplied, tested and handled?
Lazarus Labs supplies this blend as a lyophilised reference material, independently tested to 99%+ purity, with a batch Certificate of Analysis (COA). Store cold and protected from light, per standard laboratory practice.
References
- Raun K, Hansen BS, Johansen NL, et al. European Journal of Endocrinology. 1998. PMID: 9849822.
- Davenport AP, Bonner TI, Foord SM, et al. Pharmacological Reviews. 2005. PMID: 16382107.
- Alba M, Fintini D, Sagazio A, et al. American Journal of Physiology – Endocrinology and Metabolism. 2006. PMID: 16822960.
- Ionescu M, Frohman LA. Journal of Clinical Endocrinology & Metabolism. 2006. PMID: 17018654.
- Memdouh S, et al. Drug Testing and Analysis. 2021. PMID: 34665524.
- Shiimura Y, et al. Nature Structural & Molecular Biology. 2025. PMID: 39833471.
Primary literature, verified against PubMed. Citations are provided for scientific reference and do not imply any human-use indication.
Important
For research use only. Not for human or veterinary consumption. These are investigational compounds and are not approved therapeutic goods. Lazarus Labs supplies them solely as laboratory reference materials and makes no therapeutic, medical or performance claims. Nothing on this page is medical advice or a recommendation to administer these compounds to humans or animals.